Chemotherapy Resistance
Chemotherapy resistance refers to the phenomenon where cancer cells initially respond to treatment but subsequently develop mechanisms to survive and proliferate despite continued exposure to cytotoxic agents. This leads to disease recurrence and limits therapeutic options.
Mechanisms of Resistance
- Efflux Pumps: Upregulation of ATP-binding cassette (ABC) transporters (e.g., P-glycoprotein) that expel drugs from cells.
- DNA Repair Enhancement: Increased capacity to repair chemotherapy-induced DNA damage.
- Apoptosis Evasion: Mutations in apoptotic pathways (e.g., p53) preventing cell death.
- Tumor Microenvironment: Physical barriers and hypoxic conditions reducing drug efficacy.
Emerging Therapeutic Alternatives
To overcome traditional chemotherapy limitations, novel approaches are being explored, including:
- Oncolytic Virotherapy: Use of genetically modified viruses to selectively infect and lyse tumor cells while stimulating an immune response.
- Case Study: Dr. Beata Halassy
- Croatian virologist who faced recurrent aggressive breast cancer after multiple surgeries and four rounds of harsh chemotherapy.
- Pursued self-administered oncolytic virotherapy as an alternative to conventional treatment.
- Documented in Self-Administered Oncolytic Virotherapy in Recurrent Breast Cancer: Dr. Halassy’s Case.
- Highlights the potential of viral-based therapies in recurrent-breast-cancer contexts where standard protocols fail.
Clinical Implications
- Need for personalized medicine strategies to identify resistance markers early.
- Integration of non-cytotoxic therapies (e.g., immunotherapy, virotherapy) into treatment algorithms.
- Importance of monitoring tumor microenvironment dynamics during treatment.
References
- Kurzgesagt – In a Nutshell. Self-Administered Oncolytic Virotherapy in Recurrent Breast Cancer: Dr. Halassy’s Case.